Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w. In this regard, the company has enclosed a press release.
The above information is a part of company’s filings submitted to BSE.